These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 14759229

  • 21. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 22. Spotlight on amoxicillin/clavulanic acid 2000 mg/125 mg extended release (XR) in respiratory tract infections in adults.
    McCormack PL, Keating GM.
    Treat Respir Med; 2005 Jan; 4(5):361-2. PubMed ID: 16137193
    [Abstract] [Full Text] [Related]

  • 23. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media.
    Dagan R.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S127-30. PubMed ID: 17980558
    [Abstract] [Full Text] [Related]

  • 24. Elements of design: the knowledge on which we build.
    MacGowan AP.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [Abstract] [Full Text] [Related]

  • 25. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA.
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [Abstract] [Full Text] [Related]

  • 26. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
    Jacobs MR.
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
    [Abstract] [Full Text] [Related]

  • 27. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 28. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, 600 Study Group.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [Abstract] [Full Text] [Related]

  • 29. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 30. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F, Klossek JM, Peynegre R, Serrano E, Castillo L, Bobin S, Desprez D, Renault C, Neel V, Rouffiac E, Borie C.
    Presse Med; 2002 Oct 19; 31(34):1596-603. PubMed ID: 12426976
    [Abstract] [Full Text] [Related]

  • 31. Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.
    Gracia M, Martínez-Marín C, Huelves L, Giménez MJ, Aguilar L, Carcas A, Ponte C, Soriano F.
    Antimicrob Agents Chemother; 2005 Mar 19; 49(3):996-1001. PubMed ID: 15728894
    [Abstract] [Full Text] [Related]

  • 32. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J.
    J Antimicrob Chemother; 2004 Dec 19; 54(6):1148-51. PubMed ID: 15489246
    [Abstract] [Full Text] [Related]

  • 33. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep 19; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug 19; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 35. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B, Carratalà J, Tubau F, Dorca J, Liñares J, Pallares R, Manresa F, Gudiol F.
    Microb Drug Resist; 2001 Aug 19; 7(1):85-96. PubMed ID: 11310807
    [Abstract] [Full Text] [Related]

  • 36. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 1998 Sep 19; 42(9):2375-9. PubMed ID: 9736566
    [Abstract] [Full Text] [Related]

  • 37. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P, File T, Feldman C.
    Respir Med; 2004 Aug 19; 98(8):708-20. PubMed ID: 15303634
    [Abstract] [Full Text] [Related]

  • 38. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN.
    Int J Antimicrob Agents; 2005 Apr 19; 25(4):282-9. PubMed ID: 15784306
    [Abstract] [Full Text] [Related]

  • 39. Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine.
    Ibar-Bariain M, Rodríguez-Gascón A, Isla A, Solinís MA, Canut-Blasco A.
    Rev Esp Quimioter; 2019 Apr 19; 32(2):121-129. PubMed ID: 30727714
    [Abstract] [Full Text] [Related]

  • 40. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.
    Kaye CM, Allen A, Perry S, McDonagh M, Davy M, Storm K, Bird N, Dewit O.
    Clin Ther; 2001 Apr 19; 23(4):578-84. PubMed ID: 11354391
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.